<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637585</url>
  </required_header>
  <id_info>
    <org_study_id>M016455A_4145</org_study_id>
    <nct_id>NCT00637585</nct_id>
  </id_info>
  <brief_title>Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine</brief_title>
  <official_title>A Comparison of Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To examine the relative potency, onset of action and duration of action of fexofenadine HCl
      180 mg (ALLEGRA) and desloratadine 5 mg (CLARINEX) as compared to placebo on skin wheals and
      flares induced by histamine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of change in summation skin flares from baseline will be measured.</measure>
    <time_frame>Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size of change in summation skin wheals from baseline will be measured.</measure>
    <time_frame>Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24).</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>Allergic Rhinitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects, 12 to 55 years of age, may participate

          -  Positive histamine skin prick tests (or duplicate histamine skin prick test) with a
             summation flare (ΣF) greater than or equal to 20 mm larger than diluent control, and
             summation wheal (ΣW) greater than or equal to 6 mm larger than diluent control at the
             screening visit 1

          -  All female subjects must have a negative urine pregnancy test at the screening visit

          -  Female subjects who are sexually active will be expected to use one of the following
             birth control methods throughout the study (see Section 4.4)

          -  Subjects must be within 15% of normal body weight for height or a BMI less than 29.9
             (based on NHLBI guidelines)

          -  Subjects willing and able to adhere to visit schedules and all study requirements

          -  All female subjects must have a negative urine pregnancy test at each treatment visit
             (Visit 2, 4, and 6).

          -  Continues to meet all inclusion and exclusion criteria

        Exclusion Criteria:

          -  Asthma that requires treatment with medication other than an inhaled, short-acting
             beta agonist

          -  Signs and symptoms of currently active allergic disease (seasonal allergic rhinitis,
             perennial allergic rhinitis, episodic allergic rhinitis)

          -  Upper respiratory tract infection, sinusitis, asthma or flu-like symptoms within 2
             weeks prior to visit 1

          -  Subjects who have dermatographism or other skin conditions which might interfere with
             the interpretation of the skin test results

          -  Subjects who are receiving immunotherapy

          -  Any excessive amounts of alcohol (no more than two drinks/day on average)

          -  Any excessive use of caffeine (more than six cups of coffee per day or equivalent)

          -  Any use of tobacco/nicotine products within 90 days of visit 1

          -  Any disease state or surgery known to affect the gastrointestinal absorption of drugs

          -  Known hypersensitivity to the investigational product or to drugs with similar
             chemical properties

          -  Subjects who will be visiting a tanning salon during the study

          -  Subjects who will need to use artificial tanning products during the study

          -  Night or variable shift workers during the study

          -  Pregnancy

          -  Breast-feeding

          -  History of hypersensitivity to the study medications or to drugs with similar chemical
             structures

          -  Treatment with other H1-receptor antagonists in the last year before study entry

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             the clinical study protocol (see Section 6.2)

          -  Treatment with any investigational product in the last 30 days before study entry

          -  No person or child of a person directly associated with the administration of the
             study may participate as a study subject

          -  Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major
             systemic disease making implementation of the protocol or interpretation of the study
             results difficult

          -  Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study

          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study

          -  Use of any of the following drugs within the time indicated prior to the first dosing
             visit:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Diener</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

